from the finanacial crisis (E TRADE Financial Corporation (NASDAQ:ETFC)), a biotechnology company ( Celgene Corporation (NASDAQ: CELG )), and two poster children of a potential new internet bubble (Netflix, Inc. (NASDAQ:NFLX) and
Isis Pharmaceuticals ( ISIS ), Gilead ( GILD ), Celgene ( CELG ), Regeneron ( REGN ), Biogen Idec ( BIIB ), Perrigo ( PRGO ..... Idec ( BIIB ), Regeneron ( REGN ), Gilead ( GILD ), Celgene ( CELG ) 3. Consumer Frugality: Perrigo ( PRGO ) 4. Healthy Eating
Celgene Corporation ( CELG ) Cowen & Company 34th Annual Health Care Conference Call March 4, 2014 11:20 AM ET Executives Patrick Flanigan - VP, IR Perry
By Stephen Simpson, CFA : Gene therapy has generated exceptional excitement and interest over its potential for over three decades, but actual clinical progress has been painfully slow and frustrating. Bluebird Bio ( BLUE ) (and I am choosing to capitalize the name, even though it is officially ...
Speaking with three leading physicians about their plans to utilize Celgene's ( CELG +0.4% ) Otezla in psoriasis and psoriatic arthritis, analyst Matthew Roden says the feedback "generally is consistent with
higher interest rates and a stumbling broader market could see the sector slumping up to 40%. His favorites to own are Celgene ( CELG ) and Gilead ( GILD ) because of strong cash flows and very low relative multiples. Related ETFs: IBB , XBI , BIB , BBH , FBT
By Life Sciences Report : Whether biotech stocks keep up the scorching pace of 2013 remains to be seen, but we can count on one thing going forward, says Cantor Fitzgerald Senior Analyst Mara Goldstein. We are still in a catalyst-driven market. In this interview with The Life Sciences Report , ...
treatments. MiMedx's ( MDXG ) amniotic membrane products are seeing triple-digit demand growth as they continue to seize market share from legacy products. Giant pharma Celgene ( CELG ) will also target this emerging Complete Story »
Part of this rally could be explained by rumors of a potential buy-out from healthcare giants Eli Lilly ( LLY ) and Celgene ( CELG ), as well as the push for two board seats by Sarissa Capital. Company Overview: Founded in 1991, Ariad Pharmaceuticals is
By Life Sciences Report : Dhesh Govender, manager of the life sciences portfolio for Cedar Lane Enterprises Inc., has the inside track when it comes to identifying the hottest biotech trends. In this interview with The Life Sciences Report , Govender explains why he thinks plenty of upside remains